Price T Rowe Associates Inc Argenx Se Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Argenx Se stock. As of the latest transaction made, Price T Rowe Associates Inc holds 5,504,506 shares of ARGX stock, worth $2.37 Billion. This represents 0.27% of its overall portfolio holdings.
Number of Shares
5,504,506
Previous 3,673,855
49.83%
Holding current value
$2.37 Billion
Previous $1.4 Billion
55.06%
% of portfolio
0.27%
Previous 0.19%
Shares
14 transactions
Others Institutions Holding ARGX
# of Institutions
356Shares Held
31.3MCall Options Held
212KPut Options Held
210K-
Artisan Partners Limited Partnership Milwaukee, WI3.19MShares$1.37 Billion1.93% of portfolio
-
Janus Henderson Group PLC London, X02.22MShares$953 Million0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.12MShares$910 Million0.51% of portfolio
-
Capital World Investors Los Angeles, CA1.86MShares$802 Million0.13% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$533 Million5.88% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $23.8B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...